The clinical effect and prognosis of advanced non -small cell lung cancer patients with chemotherapy of nedaplatin combined gemcitabine
10.3760/cma.j.issn.1008-6706.2015.14.019
- VernacularTitle:吉西他滨联合奈达铂治疗晚期非小细胞肺癌的临床疗效及预后
- Author:
Yu WAN
;
Han ZHANG
;
Feng CHAI
- Publication Type:Journal Article
- Keywords:
Carcinoma,Non-Small Cell Lung;
Gemcitabine;
Nedaplatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;(14):2140-2142,2143
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore clinical effect of nedaplatin combined gemcitabine on chemotherapy of advanced non-small cell lung cancer (NSCLC),and to observe the prognosis and complications of these patients. Methods 106 patients with advanced NSCLC were selected,they were randomly divided into the treatment group and the control group with 53 cases each group,according to the single and double of order registration number.The con-trol group were given cisplatin combined gemcitabine chemotherapy,the treatment group were administrated nedaplatin combined gemcitabine chemotherapy,three weeks repeat.The treatment effect was estimated after two cycles of chemo-therapy,and progression-free survival ( PFS) ,patients quality of life with KPS after treatment,and the adverse reac-tions were assessed.Results The disease control rates (DCR) of the treatment group was 77.36% (41/53),the control group was 71.70%(38/53),there was no statistically significant difference (χ2 =2.46,P>0.05).PFS of the treatment group were (4.26 ±0.38) months,the control group was (3.72 ±0.30) months,there was no statisti-cally significant difference (t=2.94,P>0.05).KPS of the treatment group was (74.48 ±4.04)points,which was higher than (69.76 ±3.28)points of the control group,the difference was statistically significant (t =7.33,P<0.05).The total adverse reaction of the treatment group was 81.13%(43/53),which was lower than the control group 90.57%(48/53),the difference was statistically significant (χ2 =7.61,P<0.05).Conclusion There is preferably clinical effect of nedaplatin combined gemcitabine treatment of NSCLC,the adverse reactions was lower sig-nificantly,the patients prognosis is good,and which is worth clinical promotion.
